Logo image of ABVX

ABIVAX SA-ADR (ABVX) Stock Price, Quote, News and Overview

NASDAQ:ABVX - Nasdaq - US00370M1036 - ADR - Currency: USD

7.91  -0.38 (-4.58%)

After market: 8.124 +0.21 (+2.71%)

ABVX Quote, Performance and Key Statistics

ABIVAX SA-ADR

NASDAQ:ABVX (3/7/2025, 8:03:14 PM)

After market: 8.124 +0.21 (+2.71%)

7.91

-0.38 (-4.58%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17.02
52 Week Low5.5
Market Cap501.36M
Shares63.38M
Float57.20M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-24 2025-03-24/amc
IPO06-26 2015-06-26


ABVX short term performance overview.The bars show the price performance of ABVX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

ABVX long term performance overview.The bars show the price performance of ABVX in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ABVX is 7.91 USD. In the past month the price increased by 31.29%. In the past year, price decreased by -43.9%.

ABIVAX SA-ADR / ABVX Daily stock chart

ABVX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.17 378.30B
AMGN AMGEN INC 16.39 174.51B
GILD GILEAD SCIENCES INC 25.47 146.22B
VRTX VERTEX PHARMACEUTICALS INC 1683.76 125.39B
REGN REGENERON PHARMACEUTICALS 15.5 77.34B
ARGX ARGENX SE - ADR 231.21 36.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.66B
ONC BEIGENE LTD-ADR N/A 26.47B
BNTX BIONTECH SE-ADR N/A 26.08B
BIIB BIOGEN INC 9.13 22.01B
NTRA NATERA INC N/A 19.02B
GMAB GENMAB A/S -SP ADR 24.89 15.34B

About ABVX

Company Profile

ABVX logo image Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 62 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Company Info

ABIVAX SA-ADR

7-11 Boulevard Haussmann

Paris ILE-DE-FRANCE FR

Employees: 62

Company Website: https://www.abivax.com/

Investor Relations: http://abivax.com/investors/

Phone: 33153830963

ABIVAX SA-ADR / ABVX FAQ

What is the stock price of ABIVAX SA-ADR today?

The current stock price of ABVX is 7.91 USD. The price decreased by -4.58% in the last trading session.


What is the ticker symbol for ABIVAX SA-ADR stock?

The exchange symbol of ABIVAX SA-ADR is ABVX and it is listed on the Nasdaq exchange.


On which exchange is ABVX stock listed?

ABVX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ABIVAX SA-ADR stock?

12 analysts have analysed ABVX and the average price target is 31.49 USD. This implies a price increase of 298.13% is expected in the next year compared to the current price of 7.91. Check the ABIVAX SA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABIVAX SA-ADR worth?

ABIVAX SA-ADR (ABVX) has a market capitalization of 501.36M USD. This makes ABVX a Small Cap stock.


How many employees does ABIVAX SA-ADR have?

ABIVAX SA-ADR (ABVX) currently has 62 employees.


What are the support and resistance levels for ABIVAX SA-ADR (ABVX) stock?

ABIVAX SA-ADR (ABVX) has a support level at 7.67 and a resistance level at 8.09. Check the full technical report for a detailed analysis of ABVX support and resistance levels.


Is ABIVAX SA-ADR (ABVX) expected to grow?

The Revenue of ABIVAX SA-ADR (ABVX) is expected to grow by 628.34% in the next year. Check the estimates tab for more information on the ABVX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABIVAX SA-ADR (ABVX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABIVAX SA-ADR (ABVX) stock pay dividends?

ABVX does not pay a dividend.


When does ABIVAX SA-ADR (ABVX) report earnings?

ABIVAX SA-ADR (ABVX) will report earnings on 2025-03-24, after the market close.


What is the Price/Earnings (PE) ratio of ABIVAX SA-ADR (ABVX)?

ABIVAX SA-ADR (ABVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.45).


What is the Short Interest ratio of ABIVAX SA-ADR (ABVX) stock?

The outstanding short interest for ABIVAX SA-ADR (ABVX) is 2.02% of its float. Check the ownership tab for more information on the ABVX short interest.


ABVX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ABVX. When comparing the yearly performance of all stocks, ABVX is a bad performer in the overall market: 85.77% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ABVX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ABVX. ABVX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABVX Financial Highlights

Over the last trailing twelve months ABVX reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS decreased by -10.5% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.37%
ROE -140.29%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%10.52%
Sales Q2Q%N/A
EPS 1Y (TTM)-10.5%
Revenue 1Y (TTM)N/A

ABVX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ABVX. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -6.86% and a revenue growth 628.34% for ABVX


Ownership
Inst Owners41.83%
Ins OwnersN/A
Short Float %2.02%
Short Ratio6.62
Analysts
Analysts86.67
Price Target31.49 (298.1%)
EPS Next Y-6.86%
Revenue Next Year628.34%